Drugs / PR-1 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00893997 | Jul 2006 → Mar 2009 | leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR-1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00893997 ↗ |
| Action | Deplete | “PR1 peptide vaccine is given to help immune cells kill MDS cells.” NCT00893997 ↗ |
| Modality | Vaccine | “PR1 peptide vaccine is given to help immune cells kill MDS cells.” NCT00893997 ↗ |
| Route | Subcutaneous | “0.5 mg injections under the skin” NCT00893997 ↗ |